Phosphagenics appoints pharma veteran
By Dylan Bushell-Embling
Tuesday, 08 July, 2008
Tuesday, 08 July, 2008
Phosphagenics [ASX: POH] has appointed Michael Ashton to its board as a non-executive director.
Ashton will also act as a consultant on the Melbourne's company's commercialisation strategies.
Ashton has worked for over three decades in the international pharmaceutical industry, including having held senior management positions at Merck, Pfizer and Faulding.
Ashton also served as CEO for SkyePharma PLC.
Related News
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
